Mankind Pharma signs up with Glenmark Pharmaceuticals for co-marketing of Remogliflozin Etabonate in India
New Delhi, 23rd December 2019: Mankind Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. today inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India. Under the agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply Remogliflozin to Mankind.
In April 2019, Glenmark received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.During the trials Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin. Subsequently, Glenmark launched Remogliflozin indicated in the treatment of Type 2 diabetes mellitus in adults under the brand names ‘Remo’ and ‘Remozen’.